In the last trading session, 4.62 million Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $1.95 changed hands at $0.06 or 3.17% during last session, the market valuation stood at $116.43M. ALDX’s last price was a discount, traded about -269.23% off its 52-week high of $7.20. The share price had its 52-week low at $1.14, which suggests the last value was 41.54% up since then. When we look at Aldeyra Therapeutics Inc’s average trading volume, we note the 10-day average is 5.15 million shares, with the 3-month average coming to 1.17 million.
Analysts gave the Aldeyra Therapeutics Inc (ALDX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALDX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Aldeyra Therapeutics Inc’s EPS for the current quarter is expected to be -0.24.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Instantly ALDX was in green as seen at the end of in last trading. With action -66.09%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -60.92%, with the 5-day performance at -66.09% in the red. However, in the 30-day time frame, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is -69.29% down. Looking at the short shares, we see there were 3.99 million shares sold at short interest cover period of 6.27 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 82.27% from its current market value. According to analyst projections, ALDX’s forecast low is 10 with 12 as the target high. To hit the forecast high, the stock’s price needs a -515.38% plunge from its current level, while the stock would need to soar -412.82% for it to hit the projected low.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of -666.67k. 6 analysts are of the opinion that Aldeyra Therapeutics Inc’s revenue for the current quarter will be 30M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15.99%. The 2025 estimates are for Aldeyra Therapeutics Inc earnings to increase by 57.13%.
ALDX Dividends
Aldeyra Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-27.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.43% of Aldeyra Therapeutics Inc shares while 63.13% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 64.70%. There are 63.13% institutions holding the Aldeyra Therapeutics Inc stock share, with PERCEPTIVE ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 15.6121% of the shares, roughly 9.28 million ALDX shares worth $30.7 million.
KNOLL CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 9.2158% or 5.48 million shares worth $18.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.76 shares estimated at $3.43 million under it, the former controlled 2.95% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.16% of the shares, roughly 1.29 shares worth around $2.52 million.
